Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

Szu-Min Hsieh; Ming-Che Liu; Yen-Hsu Chen; Wen-Sen Lee; Shinn-Jang Hwang; Shu-Hsing Cheng; Wen-Chien Ko; Kao-Pin Hwang; Ning-Chi Wang; Yu-Lin Lee; Yi-Ling Lin; Shin-Ru Shih; Chung-Guei Huang; Chun-Che Liao; Jian-Jong Liang; Chih-Shin Chang; Charles Chen; Chia En Lien; I-Chen Tai; Tzou-Yien Lin

The Lancet Respiratory Medicine (2021) - Comments
doi: 10.1016/s2213-2600(21)00402-1 issn: 2213-2600 pubmed: 34655522 issn: 2213-2619

Szu-Min Hsieh, Ming-Che Liu, Yen-Hsu Chen, Wen-Sen Lee, Shinn-Jang Hwang, Shu-Hsing Cheng, Wen-Chien Ko, Kao-Pin Hwang, Ning-Chi Wang, Yu-Lin Lee, Yi-Ling Lin, Shin-Ru Shih, Chung-Guei Huang, Chun-Che Liao, Jian-Jong Liang, Chih-Shin Chang, Charles Chen, Chia En Lien, I-Chen Tai, Tzou-Yien Lin